Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12453534 | 0.89 | HTR2A (0.42) | HTR2AHTR2CMETTL3MAPK1MPO | |
| SCHEMBL1104895 | 0.89 | METTL3 (0.42) | HTR2AHTR2CMETTL3MPOMAPK10 | |
| SCHEMBL13885323 | 0.87 | HTR2A (0.49) | HTR2AHTR2CMAPK1TAAR1KDM4E | |
| SCHEMBL17265669 | 0.83 | HTR2A (0.46) | HTR2AHTR2CMAPK1TAAR1KDM4E | |
| SCHEMBL1104891 | 0.82 | METTL3 (0.56) | METTL3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4211289 | 0.81 | METTL3 (0.55) | METTL3KDM4EALDH1A1 | |
| SCHEMBL4207612 | 0.80 | METTL3 (0.50) | METTL3KDM4EALDH1A1LMNA | |
| SCHEMBL16380484 | 0.80 | METTL3 (0.46) | METTL3MPOKDM4ELMNA | |
| SCHEMBL15561430 | 0.80 | METTL3 (0.43) | HTR2AHTR2CMETTL3MPOMAPK10 | |
| SCHEMBL1104898 | 0.79 | METTL3 (0.49) | METTL3KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190804-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2069280-B1 | Process and intermediates for preparing HIV integrase inhibitors | GILEAD SCIENCES INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8796459-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2644587-A2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8440831-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130116437-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8324244-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8153801-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-7825252-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825252-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009036161-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008033836-A2 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | HTR2A 4438/4885HTR2C 3988/4885METTL3 2511/4885 |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | HTR2A 4438/4885HTR2C 3988/4885METTL3 2511/4885 |
| US-20130116437-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | HTR2A 4438/4885HTR2C 3988/4885METTL3 2511/4885 |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | HTR2A 4438/4885HTR2C 3988/4885METTL3 2511/4885 |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | HTR2A 4438/4885HTR2C 3988/4885METTL3 2511/4885 |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | HTR2A 4438/4885HTR2C 3988/4885METTL3 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.